The long-term outcome of patients with hairy cell leukemia requisite for the long-term survival of patients with hairy cell resistant to interferon-␣ (IFN-␣) following treatment with deoxyleukemia. Even so, the briefer duration of treatment needed coformycin (DCF) was examined, and the kinetics of recovery with 2-CdA and DCF make these agents more appealing of lymphocyte subsets and factors influencing the rate of choices in many circumstances. 
expression of the IL-2 receptor (CD25).
14 Patients resistant to nificant concern expressed regarding the potential adverse patients remain alive. After DCF, nadir CD4 + and CD8 + lymphoconsequences of the long-term immunosuppressive effects of cyte counts were significantly lower than prior to therapy (P Ͻ Ͻ Ͻ 0.0001 and P = 0.05, respectively), but returned to baseline DCF, particularly on T cells. [17] [18] [19] [20] [21] To address these issues, we levels during follow-up. Median times to attainment of the lower have examined the duration of remission, survival, long-term limit of the normal range of CD4 + and CD8 + lymphocytes were complications, and kinetics of recovery of CD4 + lymphocytes 54 and 36 months, respectively. Those patients who had prein a cohort of patients who have been followed for a median viously undergone splenectomy (n = 7) had higher baseline of more than 7 years after treatment with DCF for IFN-␣-resist-CD4 + (P = 0.073) and CD8 + (P = 0.043) lymphocyte counts and ant hairy cell leukemia.
16 more rapid recovery of both CD4 + (P = 0.027) and CD8 + lymphocyte counts (P = 0.016) than non-splenectomized patients. One elderly patient (age, 78 years) was diagnosed with subsequent malignancy. No late opportunistic infections were observed. Introduction Hydration with normal saline (500 to 1000 cc) was given before and after each dose. Twelve cycles (24 weeks) of therWithin the last 15 years a range of effective therapies have apy were planned. become available for patients with hairy cell leukemia.
1-5 The three most frequently used are interferon-␣ (IFN-␣), 6, 7 2-chlorodeoxyadenosine (2-CdA), 8, 9 and deoxycoformycin Patient eligibility (DCF). 10,11 All have major activity against hairy cell leukemia, though DCF and 2-CdA attain a higher rate of complete All patients had a histologic diagnosis of hairy cell leukemia remission (CR) than does IFN-␣. attainment of all of the following: (1) decrease to 1-5% bone marrow hairy cells; (2) at least a 50% reduction in palpable ongoing CR 48 months after his second treatment with 2-lymphadenopathy and splenomegaly; and (3) blood counts as CdA.) Nine patients completed the 12 cycles of DCF therapy defined for CR. Relapse was defined as the reappearance, or as planned and the remaining patients received 4, 6, 8, 8, progression to greater than 5% marrow hairy cells (for those 9, and 11 cycles of treatment. Therapy was discontinued in patients with an initial PR), or a reduction in peripheral blood responding patients for the following reasons: patient's request counts to less than those required for response, or the recurwithout objective toxicity (one case), rash (one case), signifirence of clinical evidence of hairy cell leukemia.
cant nausea (two cases), and skin rash with conjunctivitis and Duration of remission was calculated from the date hematuria (one case). response was first documented until the first documentation of relapse, or the date of most recent follow-up. At each follow-up clinic visit a thorough physical examination was perResponse duration formed. Patients were generally scheduled to be seen every 3 to 6 months for the first 2 years following treatment and then
The median duration of follow-up for all 15 patients from the every 6 to 12 months. Patient status was analyzed as of 15 beginning of DCF therapy was 88 months (range, 72 to 106 July 1995. Lymphocyte counts were dated from the last day months). Seven responding patients have manifested recurrent of administration of DCF therapy.
disease. Relapse occurred after 45 to 74 months of remission. In two cases recurrent disease was documented on routine bone marrow biopsy in the setting of normal peripheral blood Statistical analysis counts. The median time to retreatment was 81 months. The median follow-up period of patients in ongoing remission was Comparisons between groups for non-parametric data were 94 months (range, 72 to 102 months). The median remission made using the Mann-Whitney U test, and for parametric data duration of all 15 patients was 74 months and at 8 years 46% using the 2 test. Sequential studies in individual patients were (95% confidence interval, 33% to 59%) of patients are procompared using the Wilcoxon matched-pairs test. Response jected to remain in ongoing CR (Figure 1 ). There was no sigduration was calculated using the method of Kaplan and nificant difference in response duration according to prior Meier and compared using the log-rank test. Patients remainsplenectomy, number of courses of DCF received, or the presing free of relapse were considered censored at the date of last follow-up. All P values given are two-sided.
Results

Patient characteristics and response
A total of 15 IFN-␣-resistant patients were treated. Therapy was initiated between May 1986 and May 1989. These 15 patients represent all IFN-␣-resistant hairy cell leukemia patients treated with DCF at MD Anderson Cancer Center during the above time interval. All patients were considered eligible and evaluable. Baseline characteristics are shown in Table 1 . Fourteen of the 15 patients attained objective responses (overall response rate, 93%; 95% confidence interval, 68% to 100%). All responding patients achieved CR confirmed on bone marrow biopsy. Only one patient failed to attain an objective response after eight cycles of therapy. (This patient was then treated with fludarabine without response. Sub-
Figure 1
Remission duration for all 15 patients with hairy cell leusequently, he attained a 12 months CR after treatment with 2-kemia resistant to IFN-␣ treated with DCF plotted by the method of Kaplan and Meier.
CdA and was retreated with 2-CdA at relapse. He remains in ence of neutralizing IFN-␣ antibodies (all P Ͼ 0.2) (data not to six determinations per patient). Using the most recent results where more than one determination was made, testing shown). All 15 patients entered on study remain alive.
All of the seven relapsing patients have been treated with in these 14 patients was performed at a median of 61 months after completing DCF treatment (range, 4 to 94 months). Both 2-CdA. Five attained a CR and two a PR.
CD4
+ and CD8 + lymphocyte counts had returned to pre-treatment levels (P = 0.39 and 0.84, respectively, Wilcoxon matched-pairs test). The median baseline and post-treatment Lymphocyte subsets recovery time CD4
+ lymphocyte counts in these 14 patients were 705/l (range, 278 to 1387/l) and 452/l (range, 189 The percentage of CD4 + and CD8 + lymphocytes were determined by standard flow-cytometric methods and the absolute to 1186/l), respectively. Similarly, the median baseline and post-treatment recovery time CD8 + lymphocyte counts were CD4 + and CD8 + lymphocyte counts then calculated from simultaneous complete blood examinations with white cell differ-461/l (range 121 to 1477/l) and 480/l (range 101 to 1192/l), respectively. ential counts. The normal ranges for absolute CD4
+ and CD8
+ lymphocyte counts at MD Anderson Cancer Center are 365 In order to determine the duration of CD4 + and CD8 + lymphocytopenia, the time to achieve a CD4 + count of 365/l to 2400/l and 270 to 1600/l, respectively. To isolate the influence of DCF on lymphocyte subsets, data points obtained and a CD8 + count of 270/l (the lower limit of the normal range for CD4 + and CD8 + lymphocytes, respectively) were subsequent to exposure to other lymphocytotoxic agents (corticosteroids, fludarabine, 2-CdA) for management of plotted using the method of Kaplan and Meier (Figure 2 ). The median time to attain a CD4 + lymphocyte count of 365/l was relapse were not used. No patient had been treated with fludarabine or 2-CdA prior to DCF therapy and no patient had 54 months, and, at 7 years, 82% of patients (95% confidence interval, 70% to 93%) were projected to have attained such recent or concurrent treatment with corticosteroids at the time of commencing DCF. a level. CD8 + lymphocyte counts recovered at a similar rate to CD4
+ lymphocyte counts (P = 0.70). The median time to All 15 patients had lymphocyte subset determinations performed prior to commencing DCF (Table 2) . Absolute CD4 + attain a CD8
+ lymphocyte count of 270/l was 36 months and, at 7 years, 83% of patients (95% confidence interval, counts ranged from 276 to 1387/l (median 692/l), with three patients (20%) having counts less than the lower limit 72% to 94%) were projected to have attained such a level. of normal. Baseline CD8 + counts ranged from 112 to 1477/l (median 365/l), with six patients (40%) having counts less than the lower limit of normal.
Influence of splenectomy on lymphocyte subsets
Repeat analysis of lymphocyte subsets were performed in nine patients between 3 and 8 months (median, 6 months) An earlier report by Cawley et al 23 suggested that splenectomy may result in increased CD8
+ lymphocyte counts in patients after commencing DCF. These were considered to represent nadir counts in these patients. The nadir absolute CD4
+ counts with hairy cell leukemia. To investigate this possibility, the recovery of lymphocyte subsets was compared according to ranged from 9 to 292/l. All nine patients (100%) had nadir CD4 + counts below the lower limit of normal. This was very whether the patients had undergone prior splenectomy. Eight patients had previously undergone splenectomy. In seven of significantly lower than the corresponding counts in these patients at baseline (P Ͻ 0.0001, Wilcoxon matched-pairs these individuals, the spleen was removed as a diagnostic procedure. Splenectomy was performed 33 to 95 months test). Nadir CD8 + lymphocyte counts were also reduced compared to baseline (P = 0.05, Wilcoxon matched-pairs test).
(median, 50 months) prior to beginning treatment with DCF. One additional patient underwent splenectomy 29 years prior Nadir absolute CD8 + lymphocyte counts ranged from 27 to 597/l. Six of the nine patients (67%) had nadir absolute CD8 + to the diagnosis of hairy cell leukemia for unspecified reasons. Post-DCF treatment lymphocyte subset analyses were perforlymphocyte counts below the lower limit of normal.
Fourteen of the 15 patients with pre-treatment lymphocyte subset analysis had at least one repeat determination after commencing DCF therapy (mean and median, 3.0; range one The patients with prior splenectomy had significantly more Despite resistance to treatment with IFN-␣, DCF was very rapid recovery of both CD4 + (P = 0.027, log-rank test; median effective in the patients studied. A CR rate of 93% (95% contime to 365/l CD4 + cells was 32 months (splenectomized fidence interval, 68% to 100%) was achieved. This response patients) vs 83 months (patients with intact spleen); hazard rate confirms the excellent activity of DCF in patients with ratio 3.5) and CD8
+ lymphocyte counts (P = 0.016, median hairy cell leukemia resistant to IFN-␣. In the initial report by time to 270/l CD8 + cells was 29 months (splenectomized Spiers et al 10 six patients with disease refractory to IFN-␣ were patients) vs 83 months (patients with intact spleen); hazard included, three attained a CR and two a PR. Similarly Ho et ratio 3.7) (Figures 3a and b) . This may be due, at least in part, al 15 reported that 23 of 30 (77%) patients resistant to IFN-␣ to differences observed in these parameters prior to treatment attained a major objective response to DCF (33% CR and 43% with DCF. The median pretreatment CD4 + lymphocyte count PR). The largest study to evaluate DCF in IFN-␣ resistant patiwas 832/l (range, 276 to 1387/l) for splenectomized ents was the recently reported Intergroup Study. 12 This ranpatients, compared with 502/l (range, 278 to 718/l) for domized comparison of DCF and IFN-␣ specified a cross-over non-splenectomized patients (P = 0.073, Mann-Whitney U to the alternate therapy in patients failing to respond as well test). Similarly, medians for CD8
+ lymphocyte counts were as in responders with early relapse. Seventy-seven of the 86 663/l (range, 112 to 1477/l) and 198/l (range, 121 to evaluable cross-over patients (90%) attained a CR, PR or 558/l), respectively (P = 0.043, Mann-Whitney U test). There unconfirmed response. The overall response rate for DCF in were insufficient data available to compare nadir values patients resistant to IFN-␣ from these studies (80 to 90%) does according to splenectomy status. not appear to be significantly different from that achieved by initial therapy with DCF. Three of the largest studies reported to date describe response rates for initial therapy with DCF of 96% (22 of 23 patients), 24 84% (42 of 50), 25 and 92% (141 of 154).
12 Thus resistance to IFN-␣ does not diminish the Secondary malignancies and opportunistic infections response rate to subsequent therapy with DCF. This is strong evidence for true lack of cross-resistance. Furthermore, after a median of more than 7 years follow-up, our data suggest Only one patient has developed secondary malignancy during follow-up. A 78-year-old man was found to have a pleothat these responses are quite durable. The median remission duration in the current study was 74 months with 46% (95% morphic adenoma of his salivary gland 25 months after commencing treatment with DCF. The salivary gland tumor was confidence interval, 33% to 59%) of patients projected to be in continuing complete remission at 8 years. There are few treated by excision and local irradiation. He then developed a malignant fibrous histiocytoma of his calf 80 months later prior studies documenting remission duration in patients with disease resistant to IFN-␣. Golomb et al 26 have reported an (at age 85 years). He remains in ongoing CR from his hairy cell leukemia and is currently undergoing treatment of his 84% actuarial rate of progression-free survival at 36 months (95% confidence interval 68 to 93%) in a cohort of 69 patients sarcoma.
No late opportunistic infections have been observed. In with good performance status (р2) who responded to DCF. These results are to be compared with the duration of addition, there have been no infections requiring hospitalization or intravenous antibiotics nor have there been any responses attained following primary treatment with DCF. In the recent report of the Intergroup study, 117 DCF-treated unusual infections requiring repeated courses of oral antibiotics. The aggregate follow-up time of the entire cohort is patients achieved CR, and 87% of these are projected to remain alive in ongoing remission at 6 years. 12 Median follow-111 person-years after commencement of DCF therapy.
Figure 3
Influence of prior splenectomy on time to recovery of lymphocyte subsets following treatment of hairy cell leukemia with DCF. Recovery was defined as attaining the lower limit of the normal range; 365/l for CD4 + lymphocytes and 270/l for CD8 + lymphocytes. (a) CD4
+ lymphocytes (P = 0.027, log-rank test); (b) CD8 + lymphocytes (P = 0.016, log-rank test).
up duration of this cohort was 57 months. It is unclear how Other groups have suggested some patients may recover CD4 + lymphocyte counts earlier than this time. 29, 35 frequently bone marrow examinations were performed in follow-up of these patients, and as we have documented in this Despite this prolonged period of profound CD4 + lymphocytopenia, no attributable adverse events were noted in the 111 study, a proportion of relapses are first documented on bone marrow biopsy in the absence of peripheral cytopenias or person-years of follow-up. In particular, only one elderly patient developed secondary malignancy and no late opporabnormalities on clinical examination.
There have been many previous reports of significant lymtunistic infections were observed. Our data demonstrate that with a median follow-up beyond 7 years and in spite of resistphocytopenia following treatment with DCF. [17] [18] [19] [20] [21] In the current study, despite normal pre-therapy CD4
+ lymphocyte ance to IFN-␣, the majority of patients with hairy cell leukemia treated with DCF can expect to remain free of significant counts in 80% of patients, the median nadir CD4
+ lymphocyte count was only 187/l (P Ͻ 0.0001, Mann-Whitney U test) disease or treatment-related morbidity and mortality. and all patients tested had CD4
+ lymphocyte counts below the lower limit of normal. This depth of CD4 + lymphocytopenia is comparable to the median nadir values of 126/l (range 38 References to 180/l) and 54/l (range 11 to 203/l) reported previously following DCF. 20, 21 These values also appear very similar to
